DICERNA PHARMACEUTICALS, INC. January 23, 2018
Dicerna to Present at Noble Capital Markets' NobleCon14
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at NobleCon14 - Noble Capital Markets' Fourteenth Annual Investor Conference on Tuesday, January 30, 2018 at 11:30 a.m. ET. The conference will be held at the W Hotel in Fort Lauderdale, Florida.
A live webcast of the presentation can be accessed on the Investors & Media section on the Dicerna website atwww.dicerna.com. An archived replay of the webcast will be available on the Company's website after the conference.
About Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery and development of innovative, subcutaneously delivered RNAi-based therapeutics for diseases involving the liver, including rare diseases, chronic liver diseases, cardiovascular diseases, and viral infectious diseases. Dicerna is leveraging its proprietary GalXC™ RNAi technology platform to build a broad pipeline in these core therapeutic areas, focusing on target genes where connections between target gene and diseases are well understood and documented. Dicerna intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners. For more information, please visitwww.dicerna.com.
View source version onbusinesswire.com:http://www.businesswire.com/news/home/20180123005188/en/
Dicerna Pharmaceuticals, Inc.
Investors:
Rx Communications Group Paula Schwartz, 917-322-2216pschwartz@rxir.com or
Media: SmithSolve
Alex Van Rees, 973-442-1555 ext. 111alex.vanrees@smithsolve.com
Source: Dicerna Pharmaceuticals, Inc.
News Provided by Acquire Media
Dicerna Pharmaceuticals Inc. published this content on 23 January 2018 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 23 January 2018 12:49:01 UTC.
Original documenthttp://investors.dicerna.com/common/download/download.cfm?companyid=AMDA-2IH3D0&fileid=969305&filekey=E96EB97E-F8DF-4F8D-89EE-CAF957F3D6AB&filename=DRNA_News_2018_1_23_General_Releases.pdf
Public permalinkhttp://www.publicnow.com/view/5ED76227629B9E2B544FF6B281DF7BF773C5503C
